Academic Journal

Journal of Psychiatric Research

16 Papers Indexed in Blossom

Published Papers

MDMA-Assisted Therapy for Major Depressive Disorder: A Seven-Month Follow-Up Proof of Principle Trial

This long-term follow-up (n=12) of participants with moderate-to-severe major depressive disorder who received MDMA-assisted therapy (two dosing sessions integrated with nine psychotherapy sessions) found significant reductions in depression severity and functional impairment at seven months compared to baseline, with improvements maintained from the post-treatment assessment and no increases in suicidal ideation.

Published: February 1, 2026
Journal: Journal of Psychiatric Research
Authors: Kvam, T. M., Goksøyr, I. W., Rog, J., van de Vooren, I. T. J., Stewart, L. H., Autran, I., Berthold-Losleben, M., Mørch-Johnsen, L., Holst, R., Røssberg, J. I., Clausen, I., Andreassen, O. A.

Paywallindividual

The Impact of Antidepressant Discontinuation Prior to Treatment with Psilocybin for Treatment-Resistant Depression

This post hoc analysis (n=233) of a Phase II RCT investigates the impact of recent antidepressant discontinuation (n=156) on the efficacy of psilocybin in treating treatment-resistant depression (TRD). The study compares outcomes between participants who discontinued antidepressants during screening and those who entered the trial free of these medications, finding no significant relationship between antidepressant discontinuation and worsening depression severity or compromised psilocybin treatment efficacy.

Published: December 1, 2024
Journal: Journal of Psychiatric Research
Authors: Croal, M., Goodwin, G. M., Marwood, L., Mistry, S., Simmons, H., Tsai, J., Young, M. B.

Paywallindividual

Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation - Clinical and safety results

This double-blind, randomised study (n=27) assessed the antidepressant effects of a novel oral prolonged-release formulation of racemic ketamine (KET01) in TRD patients as add-on therapy. Patients received either 160 mg/day or 240 mg/day KET01 or placebo for 14 days, with the primary endpoint being the change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from baseline to day 15. Results suggest a positive trend towards antidepressant efficacy with 240 mg/day KET01.

Published: May 1, 2024
Journal: Journal of Psychiatric Research
Authors: Adank, A., Bankwitz, A., Brühl, A. B., Colla, M., Eicher, C., Kronenberg, G., Mikoteit, T., Mutschler, J., Offenhammer, B., Schaekel, L., Scheerer, H., Seifritz, E., Vetter, S.

Paywallindividual

Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder

This open-label study (n=12) of patients suffering from Body dysmorphic disorder (BDD), an obsessive preoccupation with misperceptions of appearance, finds that psilocybin (25mg) plus psychological support (6 sessions) resulted in a response (>30% decrease in BDD-YBOCS) in 58% of participants. Secondary measures such as negative affect, disability, and conviction of belief also significantly decreased.

Published: May 1, 2023
Journal: Journal of Psychiatric Research
Authors: Cornejo, G., Feusner, J. D., Gomez, G. J., Hellerstein, D. J., Naraindas, A. M., Schneider, F., Wheaton, M. G.

Paywallmeta

Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis

This meta-analysis (2022) assessed the effectiveness of ketamine for treatment-resistant depression (TRD) using real-world data. While the mean antidepressant effect of ketamine was found to be significant, there are high levels of variability between patients. Treatment effects were found to be similar following repeated treatments.

Published: June 7, 2022
Journal: Journal of Psychiatric Research
Authors: Alnefeesi, Y., Cao, B., Ceban, F., Chen-Li, D., Di Vincenzo, J. D., Gill, H., Ho, R., Jawad, M. Y., Lee, Y., McIntyre, R. S., Meshkat, S., Rosenblat, J. D., Teopiz, K. M.

Open Accessindividual

MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD

This trial (n=90) used the Eating Attitudes Test (EAT-26) to assess the impact MDMA-assisted therapy has on symptoms of eating disorders (ED) in participants with PTSD. There was a significant reduction in total EAT-26 scores in the total group of PTSD participants following MDMA-AT versus placebo (p = .03). Overall, MDMA-AT significantly reduced ED symptoms compared to therapy with placebo among participants with severe PTSD.

Published: May 1, 2022
Journal: Journal of Psychiatric Research
Authors: Brewerton, T. D., Doblin, R., Emerson, A., Lafrance, A., Mithoefer, M. C., Wang, J. B., Yazar-Klosinski, B.

Quick Facts

Papers Indexed: 16
h-Index: 172
Open Access: No
Publisher: Elsevier
Country: United Kingdom
Website: Visit

Journal of Psychiatric Research

Published Papers

MDMA-Assisted Therapy for Major Depressive Disorder: A Seven-Month Follow-Up Proof of Principle Trial

The Impact of Antidepressant Discontinuation Prior to Treatment with Psilocybin for Treatment-Resistant Depression

Oral prolonged-release ketamine in treatment-resistant depression - A double-blind randomized placebo-controlled multicentre trial of KET01, a novel ketamine formulation - Clinical and safety results

Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder

Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis

MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD

Quick Facts

Company

Product

Legal